Subscribe to Science Friday
There’s a new trend in the world of weight loss: microdosing GLP-1 drugs. Online health clinics are promising big results with microdoses drugs like Ozempic, Wegovy, and Zepbound. Many source their drugs from compounding pharmacies, which can get complicated because compounding pharmacies are able to create different doses and formulations that haven’t gone through the FDA approval process.
So, what do we know about the safety and efficacy of microdosing GLP-1s? And is there research to back up this approach? Flora talks with two experts to help sort through what we do and don’t know: pharmacist Joey Mattingly, who studies compounded GLP-1 drugs and how they’re marketed to patients, and obesity medicine physician Jorge Moreno.
Donate To Science Friday
Invest in quality science journalism by making a donation to Science Friday.
Segment Guests
Joey Mattingly
Dr. Joey Mattingly is a pharmacist studying compounded GLP-1 drugs, and an associate professor of pharmacotherapy at the University of Utah.
Jorge Moreno
Dr. Jorge Moreno is an obesity medicine physician and an assistant professor at the Yale University School of Medicine.
Segment Transcript
The transcript is being processed. It will be available 2-3 days after this story’s publication date.
Meet the Producers and Host
About Flora Lichtman
Flora Lichtman is a host of Science Friday. In a previous life, she lived on a research ship where apertivi were served on the top deck, hoisted there via pulley by the ship’s chef.
About Shoshannah Buxbaum
Shoshannah Buxbaum is a producer for Science Friday. She’s particularly drawn to stories about health, psychology, and the environment. She’s a proud New Jersey native and will happily share her opinions on why the state is deserving of a little more love.